HilleVax Future Growth
Future criteria checks 0/6
HilleVax is forecast to grow earnings and revenue by 14.8% and 100.3% per annum respectively. EPS is expected to grow by 28.2% per annum. Return on equity is forecast to be -97.8% in 3 years.
Key information
14.8%
Earnings growth rate
28.2%
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | 100.3% |
| Future return on equity | -97.8% |
| Analyst coverage | Low |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -90 | -99 | -100 | 4 |
| 12/31/2025 | N/A | -85 | -96 | -95 | 4 |
| 12/31/2024 | N/A | -130 | -131 | -116 | 4 |
| 9/30/2024 | N/A | -150 | -129 | -112 | N/A |
| 6/30/2024 | N/A | -156 | -128 | -111 | N/A |
| 3/31/2024 | N/A | -144 | -126 | -104 | N/A |
| 12/31/2023 | N/A | -124 | -98 | -87 | N/A |
| 9/30/2023 | N/A | -108 | -98 | -84 | N/A |
| 6/30/2023 | N/A | -93 | -88 | -76 | N/A |
| 3/31/2023 | N/A | -119 | -74 | -67 | N/A |
| 12/31/2022 | N/A | -160 | -69 | -62 | N/A |
| 9/30/2022 | N/A | -176 | -50 | -48 | N/A |
| 6/30/2022 | N/A | -221 | -35 | -30 | N/A |
| 3/31/2022 | N/A | -169 | -23 | -18 | N/A |
| 12/31/2021 | N/A | -102 | -10 | -7 | N/A |
| 9/30/2021 | N/A | -66 | -6 | -3 | N/A |
| 12/31/2020 | N/A | -2 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLVX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HLVX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HLVX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HLVX is forecast to have no revenue next year.
High Growth Revenue: HLVX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLVX is forecast to be unprofitable in 3 years.